Skip to main content

Ventral Hernia Repair

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
Gemcitabine/ clindamycinPhase 31 trial
Active Trials
NCT03945357Completed250Est. Jan 2023
Sofregen Medical
Sofregen MedicalMA - Framingham
1 program
Silk surgical meshN/A1 trial
Active Trials
NCT01981044Terminated1Est. Feb 2016
Distalmotion
DistalmotionSwitzerland - Epalinges
1 program
ventral hernia repairN/A1 trial
Active Trials
NCT07071740Completed33Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Oregon TherapeuticsGemcitabine/ clindamycin
Distalmotionventral hernia repair
Sofregen MedicalSilk surgical mesh

Clinical Trials (3)

Total enrollment: 284 patients across 3 trials

NCT03945357Oregon TherapeuticsGemcitabine/ clindamycin

Reducing INfection at the Surgical SitE With Antibiotic Irrigation During Ventral Hernia Repair (RINSE Trial)

Start: May 2019Est. completion: Jan 2023250 patients
Phase 3Completed
NCT07071740Distalmotionventral hernia repair

Robotic Minimally Invasive Ventral Hernia Repair With DEXTER

Start: Jun 2025Est. completion: Jan 202633 patients
N/ACompleted
NCT01981044Sofregen MedicalSilk surgical mesh

SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair

Start: Sep 2013Est. completion: Feb 20161 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.